GRI Bio Inc. (NASDAQ: GRI) announced additional data from its Phase 2a clinical trial evaluating GRI-0621 for idiopathic pulmonary fibrosis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE